Astaxanthin Reduces Stemness Markers in BT20 and T47D Breast Cancer Stem Cells by Inhibiting Expression of Pontin and Mutant p53
Open Access
- 20 November 2020
- journal article
- research article
- Published by MDPI AG in Marine Drugs
- Vol. 18 (11) , 577
Abstract
Astaxanthin (AST) is a product made from marine organisms that has been used as an anti-cancer supplement. It reduces pontin expression and induces apoptosis in SKBR3, a breast cancer cell line. Using Western blotting and qRT-PCR analyses, this study revealed that in the T47D and BT20 breast cancer cell lines, AST inhibits expression of pontin and mutp53, as well as the Oct4 and Nanog cancer stem cell (CSC) stemness genes. In addition, we explored the mechanism by which AST eradicates breast cancer cells using pontin siRNAs. Pontin knockdown by pontin siRNA reduced proliferation, Oct4 and Nanog expression, colony and spheroid formation, and migration and invasion abilities in breast cancer cells. In addition, reductions in Oct4, Nanog, and mutp53 expression following rottlerin treatment confirmed the role of pontin in these cells. Therefore, pontin may play a central role in the regulation of CSC properties and in cell proliferation following AST treatment. Taken together, these findings demonstrate that AST can repress CSC stemness genes in breast cancer cells, which implies that AST therapy could be used to improve the efficacy of other anti-cancer therapies against breast cancer cells.Keywords
This publication has 45 references indexed in Scilit:
- p53, Stem Cells, and Reprogramming: Tumor Suppression beyond Guarding the GenomeGenes & Cancer, 2011
- Astaxanthin: A Potential Therapeutic Agent in Cardiovascular DiseaseMarine Drugs, 2011
- EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancerOncogene, 2010
- The AAA+ superfamily—a myriad of motionsCurrent Opinion in Structural Biology, 2007
- Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinomaCancer, 2005
- Regulatory networks in embryo-derived pluripotent stem cellsNature Reviews Molecular Cell Biology, 2005
- Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol)Clinical Cancer Research, 2005
- Functional Expression Cloning of Nanog, a Pluripotency Sustaining Factor in Embryonic Stem CellsCell, 2003
- Causal attributions, coping strategies, and adjustment to breast cancerCancer Nursing, 1996
- New type of POU domain in germ line-specific protein Oct-4Nature, 1990